Piotr Sobieszczyk, MD
Interventional Cardiology · Boston, MANPI 1619934031
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,710 of the $2,324 with a category attached, or 73.6%. Abbott accounts for 68.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $1,736 and has fallen 96.2% since, to $65 in 2025. That places this record below the midpoint for interventional cardiology clinicians in MA, where the typical reported total is $3,030.
Across 17 payments — averaging $136.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Medtronic$263
- Inari Medical, Inc.$170
- United Therapeutics Corporation$103
- Philips North America LLC$95
- Stryker$49
- plus $61 from 2 others
Across 1 payment — averaging $20,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$20K
What the payments were for
- Travel & lodging$1,71074%
- Food & beverage$61426%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 5 | $1,582 |
| Medtronic(2 entities) | 5 | $263 |
| Inari Medical, Inc. | 1 | $170 |
| United Therapeutics Corporation | 1 | $103 |
| Philips North America LLC | 1 | $95 |
| Stryker | 2 | $49 |
| Edwards Lifesciences | 1 | $33 |
| Boston Scientific | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,324 in reported general payments places this provider in the 45th percentile of 128 interventional cardiology providers in Massachusetts.
See all interventional cardiology providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 35 | $40,493 |
| XareltoRivaroxaban | 22 | $27,562 |
| Rosuvastatin Calcium | 30 | $1,296 |
| Ezetimibe | 20 | $1,103 |
| Atorvastatin Calcium | 68 | $982 |
| Metoprolol Succinate | 37 | $647 |
| Losartan Potassium | 20 | $227 |
| Amlodipine Besylate | 19 | $214 |
| ClopidogrelClopidogrel Bisulfate | 14 | $210 |
| Carvedilol | 21 | $204 |
| Lisinopril | 25 | $166 |
| Bumetanide | 11 | $130 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 13 | $72 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Boston
- Eric SecemskyBoston$1.2M
- Darshan DoshiBoston$730K
- Charles GibsonBoston$661K
- Duane PintoBoston$491K
- Robert YehBoston$412K
- Suzanne BaronBoston$274K
- Farouc JafferBoston$213K
- Joseph GarasicBoston$152K
- Pinak ShahBoston$147K
- Douglas DrachmanBoston$132K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.